Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Amalgamated Financial Corp is a banks-regional business based in the US. Amalgamated Financial shares (AMAL) are listed on the NASDAQ and all prices are listed in US Dollars. Amalgamated Financial employs 370 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$17.07|
|52-week range||$10.29 - $20.02|
|50-day moving average||$15.21|
|200-day moving average||$15.78|
|Wall St. target price||$18.40|
|Dividend yield||$0.32 (1.98%)|
|Earnings per share (TTM)||$1.56|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||2.46%|
|1 month (2021-09-16)||22.45%|
|3 months (2021-07-16)||9.00%|
|6 months (2021-04-16)||1.31%|
|1 year (2020-10-16)||43.93%|
|2 years (2019-10-16)||-0.58%|
|3 years (2018-10-16)||20.06|
|5 years (2016-10-12)||N/A|
Valuing Amalgamated Financial stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Amalgamated Financial's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Amalgamated Financial's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 11x. In other words, Amalgamated Financial shares trade at around 11x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Revenue TTM||$200.5 million|
|Operating margin TTM||36.42%|
|Gross profit TTM||$195.8 million|
|Return on assets TTM||0.75%|
|Return on equity TTM||9.29%|
|Market capitalisation||$518.1 million|
TTM: trailing 12 months
There are currently 219,427 Amalgamated Financial shares held short by investors – that's known as Amalgamated Financial's "short interest". This figure is 42.2% up from 154,351 last month.
There are a few different ways that this level of interest in shorting Amalgamated Financial shares can be evaluated.
Amalgamated Financial's "short interest ratio" (SIR) is the quantity of Amalgamated Financial shares currently shorted divided by the average quantity of Amalgamated Financial shares traded daily (recently around 55976.275510204). Amalgamated Financial's SIR currently stands at 3.92. In other words for every 100,000 Amalgamated Financial shares traded daily on the market, roughly 3920 shares are currently held short.
However Amalgamated Financial's short interest can also be evaluated against the total number of Amalgamated Financial shares, or, against the total number of tradable Amalgamated Financial shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Amalgamated Financial's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Amalgamated Financial shares in existence, roughly 10 shares are currently held short) or 0.0173% of the tradable shares (for every 100,000 tradable Amalgamated Financial shares, roughly 17 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Amalgamated Financial.
Find out more about how you can short Amalgamated Financial stock.
Dividend payout ratio: 18.71% of net profits
Recently Amalgamated Financial has paid out, on average, around 18.71% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.98% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Amalgamated Financial shareholders could enjoy a 1.98% return on their shares, in the form of dividend payments. In Amalgamated Financial's case, that would currently equate to about $0.32 per share.
While Amalgamated Financial's payout ratio might seem low, this can signify that Amalgamated Financial is investing more in its future growth.
Amalgamated Financial's most recent dividend payout was on 31 August 2021. The latest dividend was paid out to all shareholders who bought their shares by 16 August 2021 (the "ex-dividend date").
Amalgamated Financial's shares were split on a 20:1 basis on 29 July 2018. So if you had owned 1 share the day before before the split, the next day you'd have owned 20 shares. This wouldn't directly have changed the overall worth of your Amalgamated Financial shares – just the quantity. However, indirectly, the new 95% lower share price could have impacted the market appetite for Amalgamated Financial shares which in turn could have impacted Amalgamated Financial's share price.
Over the last 12 months, Amalgamated Financial's shares have ranged in value from as little as $10.292 up to $20.016. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amalgamated Financial's is 0.837. This would suggest that Amalgamated Financial's shares are less volatile than average (for this exchange).
Amalgamated Financial Corp. operates as a bank holding company for Amalgamated Bank that provides commercial banking and trust services for commercial and retail customers in the United States. The company accepts various deposit products, including non-interest and interest-bearing demand accounts, savings and money market accounts, NOW accounts, and certificates of deposit. It also provides various commercial loans comprising commercial and industrial, multifamily mortgage, and commercial real estate loans; and retail loans, such as residential real estate, and consumer and other loans. In addition, the company offers online banking, bill payment, online cash management, and safe deposit box rental services; debit, prepaid, and ATM cards; and trust, custody, and investment management services comprising asset safekeeping, corporate actions, income collections, proxy, account transition, asset transfers, and conversion management services. Further, it provides investment products, such as equity, fixed-income, real estate, and alternative investment products; and brokerage, asset management, and insurance products. It serves advocacy-based non-profits, social welfare organizations, labor unions, political organizations, foundations, sustainability-focused, socially responsible businesses, and other for-profit companies, as well as their members and stakeholders.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.